Investigation on the role of the tetrazole in the binding of thiotetrazolylacetanilides with HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 4, 2009, Pages 1199-1205

  Gagnon, Alexandre ^a   Landry, Serge ^a   Coulombe, René ^a   Jakalian, Araz ^a   Guse, Ingrid ^a   Thavonekham, Bounkham ^a   Bonneau, Pierre R ^a   Yoakim, Christiane ^a   Simoneau, Bruno ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

Double mutant reverse transcriptase; Electrostatic potential; Molecular modeling; Non nucleoside reverse transcriptase inhibitors (NNRTIs); Thiotetrazoles

Indexed keywords

ARYLTHIOTETRAZOLYLACETANILIDE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIOTETRAZOLYLACETANILIDE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITOR INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANTI-HIV AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; HIV REVERSE TRANSCRIPTASE; HIV-1; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 59649115687     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.12.074     Document Type: Article

References (28)

1. AIDS epidemic update, UNAIDS, World health organization, December 2007, http://www.unaids.org.
2. For a review on recent developments in the treatment of AIDS, see:. Armbruster C. Anti-Infective Agents Med. Chem. 7 (2008) 201
3. For an excellent review on the HIV-RT, see:. Castro H.C., Loureiro N.I.V., Pujol-Luz M., Souza A.M.T., Albuquerque M.G., Santos D.O., Cabral L.M., Frugulhetti I.C., and Rodrigues C.R. Curr. Med. Chem. 13 (2006) 313
4. For a recent reference on the mechanism of NNRTIs, see:. Sluis-Cremer N., and Tachedjian G. Virus Res. 134 (2008) 147
5. For excellent reviews on the current status of NNRTIs, see:. Martins S., Ramos M.J., and Fernandes P.A. Curr. Med. Chem. 15 (2008) 1083
6. Sweeney Z.K., and Klumpp K. Curr. Opin. Drug Discov. Dev. 11 (2008) 458
7. Sahlberg C., and Zhou X.-X. Anti-Infective Agents Med. Chem. 7 (2008) 101
8. Simoneau, B.; Thavonekham, B.; Landry, S.; O'Meara, J.; Yoakim, C.; Faucher, A. -M. 2004 WO 2004/050643.
9. Muraglia E., Kinzel O.D., Laufer R., Miller M.D., Moyer G., Munshi V., Orvieto F., Palumbi M.C., Pescatore G., Rowley M., Williams P.D., and Summa V. Bioorg. Med. Chem. Lett. 16 (2006) 2748
10. Shaw-Reid, C. A.; Miller, M. D.; Hazuda, D. J.; Ferrer, M.; Sur, S. M.; Summa, V.; Lyle, T. A.; Kinzel, O.; Pescatore, G.; Muraglia, E.; Orvieto, F.; Williams, P. D. 2005 WO 2005/115147.
11. For a review on RT mutations, see:. Martinez-Picado J., and Martínez M.A. Virus Res. 134 (2008) 104
12. For general reviews on resistance to current HIV therapies, see:. Shafer R.W., and Schapiro J.M. AIDS Rev. 10 (2008) 67
13. Perno C.-F., Moyle G., Tsoukas C., Ratanasuwan W., Gatell J., and Schechter M. J. Med. Virol. 80 (2008) 565
14. DeRoy, P.; Faucher, A. -M.; Gagnon, A.; Landry, S.; Morin, S.; O'Meara, J.; Simoneau, B.; Thavonekham, B.; Yoakim, C. 2005 WO 2005/118575.
15. Gagnon A., Amad M.H., Bonneau P.R., Coulombe R., DeRoy P.L., Doyon L., Duan J., Garneau M., Guse I., Jakalian A., Jolicoeur E., Landry S., Malenfant E., Simoneau B., and Yoakim C. Bioorg. Med. Chem. Lett. 17 (2007) 4437
16. O'Meara J.A., Jakalian A., LaPlante S., Bonneau P.R., Coulombe R., Faucher A.-M., Guse I., Landry S., Racine J., Simoneau B., Thavonekham B., and Yoakim C. Bioorg. Med. Chem. Lett. 17 (2007) 3362
17. Girardet, J. L.; Zhang, Z.; Hamatake, R.; Hernandez, M. A. De la Rosa; Gunic, E.; Hong, Z.; Kim, H; Koh, Y. -h.; Nilar, S.; Shaw, S.; Yao, N. 2004 WO 2004/030611.
18. Wang Z., Wu B., Kuhen K.L., Bursulaya B., Nguyen T.N., Nguyen D.G., and He Y. Bioorg. Med. Chem. Lett. 16 (2006) 4174
19. De La. Rosa M., Kim H.W., Gunic E., Jenket C., Boyle U., Koh Y.-h., Korboukh I., Allan M., Zhang W., Chen H., Xu W., Nilar S., Yao N., Hamatake R., Lang S.A., Hong Z., Zhang Z., and Girardet J.-L. Bioorg. Med. Chem. Lett. 16 (2006) 4444
20. Zhang Z., Xu W., Koh Y.-H., Shim J.H., Girardet J.-L., Yeh L.-T., Hamatake R.K., and Hong Z. Antimicrob. Agents Chemother. 51 (2007) 429
21. Zhan P., Liu X., Cao Y., Wang Y., Pannecouque C., and De Clercq E. Bioorg. Med. Chem. Lett. 18 (2008) 5368
22. 3H-dGTP at 37 ̊C.
23. For compound 28, a 28-fold and a 5-fold loss of potency was observed, respectively, for K103N and Y181C single mutants, suggesting that the loss of potency against the K103N/Y181C double mutant is mainly due to the 103 mutation.
24. 50 determinations, C8166 cells were acutely infected (MOI 0.001) and incubated with inhibitors for 3 days at 37 °C. Viral replication was assessed by p24 ELISA of the culture supernatants.
25. Models of 27 and 40 were generated by modifying an unpublished in-house X-ray structure of a related compound. Mutations K103N and Y181C were performed in silico based on pdb 1FKP and 1UWB, respectively. Energy minimization was performed on the binding site for each inhibitor/mutation complex.
26. For studies on related C-H····O{double bond, long}C interactions, see:. Tóth G., Bowers S.G., Truong A.P., and Probst G. Curr. Pharm. Design 13 (2007) 3476
27. Panigrahi S.K., and Desiraju G.R. Proteins: Structure, Function, and Bioinformatics 67 (2007) 128
28. Brandl M., Weiss M.S., Jabs A., Sühnel J., and Hilgenfeld R. J. Mol. Biol. 307 (2001) 357